Metabolites as extracellular vesicle cargo in health, cancer, pleural effusion, and cardiovascular diseases: An emerging field of study to diagnostic and therapeutic purposes

Zhang, Yan; Li, Feng; Zhang, DuoDuo; Qi, Shuang; Liu, Yan

doi:10.1016/j.biopha.2022.114046

Cited by 26 publications

(10 citation statements)

References 309 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That study reported decreased plasma tryptophan in the plasma of addicted rats, a consistent finding with our observations after acute intake while contrasting with our data from tolerant mice [ 19 ]. Furthermore, extracellular vesicles (EVs) are natural carriers of metabolites that play a vital role in various cellular signaling pathways in the context of drug abuse [ 23 , 40 , 41 , 42 , 43 ]. The potential role of EV-associated metabolites in morphine tolerance warrants further investigation.…”

Section: Discussionmentioning

confidence: 99%

Changes in Plasma Metabolic Signature upon Acute and Chronic Morphine Administration in Morphine-Tolerant Mice

Kutchy

Palermo

et al. 2023

Metabolites

View full text Add to dashboard Cite

Morphine administration causes system-level metabolic changes. Here, we show that morphine-tolerant mice exhibited distinct plasma metabolic signatures upon acute and chronic administration. We utilized a mouse model of morphine tolerance by exposing mice to increasing doses of the drug over 4 days. We collected plasma samples from mice undergoing acute or chronic morphine or saline injections and analyzed them using targeted GC–MS-based metabolomics to profile approximately 80 metabolites involved in the central carbon, amino acid, nucleotide, and lipid metabolism. Our findings reveal distinct alterations in plasma metabolite concentrations in response to acute or chronic morphine intake, and these changes were linked to the development of tolerance to morphine’s analgesic effects. We identified several metabolites that had been differentially affected by acute versus chronic morphine use, suggesting that metabolic changes may be mitigated by prolonged exposure to the drug. Morphine-tolerant mice showed a restoration of amino acid and glycolytic metabolites. Additionally, we conducted reconstructed metabolic network analysis on the first 30 VIP-ranked metabolites from the PLSDA of the saline, acute, and morphine-tolerant mice groups, which uncovered four interaction networks involving the amino acid metabolism, the TCA cycle, the glutamine-phenylalanine-tyrosine pathway, and glycolysis. These pathways were responsible for the metabolic differences observed following distinct morphine administration regimens. Overall, this study provides a valuable resource for future investigations into the role of metabolites in morphine-induced analgesia and associated effects following acute or chronic use in mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in Plasma Metabolic Signature upon Acute and Chronic Morphine Administration in Morphine-Tolerant Mice

Kutchy

Palermo

et al. 2023

Metabolites

View full text Add to dashboard Cite

show abstract

“…EVs enriched with ribose-5-phosphate and pentose phosphate pathways enzymes, may support immune cell proliferation during MI ( 4 , 56 ). Indeed, many other small sugar, amino acid, and nucleotide metabolites have been discovered in EVs, depending on the source, size, and cardiovascular disease context ( 60 ).…”

Section: Potential Interactions Of Extracellular Vesicles and Immune ...mentioning

confidence: 99%

Immunometabolism, extracellular vesicles and cardiac injury

Omoto,

do Carmo,

da Silva

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Recent evidence from our lab and others suggests that metabolic reprogramming of immune cells drives changes in immune cell phenotypes along the inflammatory-to-reparative spectrum and plays a critical role in mediating the inflammatory responses to cardiac injury (e.g. hypertension, myocardial infarction). However, the factors that drive metabolic reprogramming in immune cells are not fully understood. Extracellular vesicles (EVs) are recognized for their ability to transfer cargo such as microRNAs from remote sites to influence cardiac remodeling. Furthermore, conditions such as obesity and metabolic syndrome, which are implicated in the majority of cardiovascular disease (CVD) cases, can skew production of EVs toward pro-inflammatory phenotypes. In this mini-review, we discuss the mechanisms by which EVs may influence immune cell metabolism during cardiac injury and factors associated with obesity and the metabolic syndrome that can disrupt normal EV function. We also discuss potential sources of cardio-protective and anti-inflammatory EVs, such as brown adipose tissue. Finally, we discuss implications for future therapeutics.

show abstract

“…Recent investigations have exhibited the impact of EVs in diverse physiological and pathological states, including immune responses, viral pathogenicity, cardiovascular diseases, central nervous system‐related ailments, and cancer progression (Bahmani & Ullah, 2022; Khawar et al, 2019; Zhang et al, 2023). Furthermore, EVs derived from immunomodulatory cells have demonstrated auspicious therapeutic properties in the management of diseases such as inflammatory diseases, cancers, and others.…”

Section: The Beneficial Characteristics Of Mscsmentioning

confidence: 99%

Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney

Saadh,

Alhuthali,

Gonzales Aníbal

et al. 2023

Cell Biology International

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are recognized for their remarkable ability to differentiate into multiple cell types. They are also known to possess properties that can fight cancer, leading to attempts to modify MSCs for use in anticancer treatments. However, MSCs have also been found to participate in pathways that promote tumor growth. Many studies have been conducted to explore the potential of MSCs for clinical applications, but the results have been inconclusive, possibly due to the diverse nature of MSC populations. Furthermore, the conflicting roles of MSCs in inhibiting tumors and promoting tumor growth hinder their adaptation to anticancer therapies. Antitumorigenic and protumorigenic properties of MSCs in urological cancers such as bladder, prostate, and renal are not as well established, and data comparing them are still limited. MSCs hold significant promise as a vehicle for delivering anticancer agents and suicide genes to tumors. Presently, numerous studies have concentrated on the products derived from MSCs, such as extracellular vesicles (EVs), as a form of cell‐free therapy. This work aimed to review and discuss the current knowledge of MSCs and their EVs in urological cancer therapy.

show abstract

Metabolites as extracellular vesicle cargo in health, cancer, pleural effusion, and cardiovascular diseases: An emerging field of study to diagnostic and therapeutic purposes

Cited by 26 publications

References 309 publications

Changes in Plasma Metabolic Signature upon Acute and Chronic Morphine Administration in Morphine-Tolerant Mice

Changes in Plasma Metabolic Signature upon Acute and Chronic Morphine Administration in Morphine-Tolerant Mice

Immunometabolism, extracellular vesicles and cardiac injury

Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney

Contact Info

Product

Resources

About